Antiplatelet therapy: Views from the experts

Neurology

Volumn 53, Issue 7 SUPPL. 4, 1999, Pages

  Easton, J Donald ^a   Diener, Hans Christoph ^b   Bornstein, Natan M ⁱ   Einhäupl, Karl ^c   Gent, Michael ^d   Kaste, Markku ^e   Sacco, Ralph L ^f   Tijssen, Jan G P ^g   Van Gijn, Jan ^h  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ Brown University School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DIPYRIDAMOLE; SULFINPYRAZONE; TICLOPIDINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

EID: 0032717861     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114(suppl 5):683S-698S.
2. Goldstein LB, Bonito AJ, Matchar DB, et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: design, service availability, and common practices. Stroke 1995;26:1607-1615.
3. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
4. Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994;25:275-277.
5. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
7. Busch M, Masuhr F, Einhäupl KM. Medical and surgical prevention of stroke: experiences around the world. Cerebrovasc Dis 1997;7(suppl 1):22-28.
8. Masuhr F, Busch M, Einhäupl KM. Differences in medical and surgical therapy for stroke prevention between leading experts in North American and Western Europe. Stroke 1998;29: 339-345.
9. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
11. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
12. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321:501-507.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
14. Bennett CL, Weinberg PD, Brozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128:541-544.